sacubitril Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
endopeptidase inhibitors 5012 149709-62-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sacubitril
  • AHU377
  • sucabitril
inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite and leads to increased levels of peptides that are degraded by neprilysin such as natriuretic peptides
  • Molecular weight: 411.50
  • Formula: C24H29NO5
  • CLOGP: 4.47
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 92.70
  • ALOGS: -5.64
  • ROTB: 12

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 19, 2015 EMA
July 7, 2015 FDA NOVARTIS PHARMS CORP

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypotension 913.29 20.66 754 18349 231835 46435124
Cardiac failure 575.49 20.66 375 18728 79573 46587386
Wrong technique in product usage process 346.96 20.66 237 18866 54185 46612774
Death 280.48 20.66 495 18608 335053 46331906
Dizziness 251.23 20.66 476 18627 339938 46327021
Dyspnoea 238.98 20.66 597 18506 514951 46152008
Ejection fraction decreased 222.98 20.66 120 18983 17817 46649142
Cough 222.75 20.66 363 18740 229886 46437073
Angioedema 190.25 20.66 145 18958 39197 46627762
Blood pressure decreased 185.21 20.66 167 18936 56992 46609967
Cardiac failure chronic 172.73 20.66 62 19041 3462 46663497
Product prescribing error 171.14 20.66 105 18998 19942 46647017
Blood potassium increased 155.47 20.66 93 19010 16874 46650085
Inappropriate schedule of product administration 134.72 20.66 149 18954 64864 46602095
N-terminal prohormone brain natriuretic peptide increased 122.56 20.66 40 19063 1671 46665288
Glomerular filtration rate decreased 112.08 20.66 66 19037 11628 46655331
No adverse event 108.80 20.66 99 19004 34132 46632827
Blood creatinine increased 106.01 20.66 143 18960 76260 46590699
Atrial fibrillation 102.03 20.66 165 18938 103425 46563534
Hyperkalaemia 99.49 20.66 113 18990 50596 46616363
Fluid retention 95.52 20.66 111 18992 50935 46616024
Cardiac disorder 89.90 20.66 100 19003 43758 46623201
Weight increased 88.91 20.66 203 18900 164270 46502689
Prescribed underdose 82.64 20.66 55 19048 11998 46654961
Renal impairment 80.86 20.66 124 18979 74248 46592711
Ejection fraction abnormal 76.38 20.66 22 19081 600 46666359
Malaise 76.23 20.66 302 18801 330930 46336029
Concomitant disease aggravated 74.25 20.66 44 19059 7838 46659121
Fatigue 66.33 20.66 450 18653 608247 46058712
Rheumatoid arthritis 65.64 20.66 10 19093 240205 46426754
Toxicity to various agents 64.80 20.66 6 19097 211760 46455199
Underdose 62.97 20.66 57 19046 19501 46647458
Myocardial infarction 58.97 20.66 126 18977 97402 46569557
Basilar artery occlusion 57.68 20.66 13 19090 126 46666833
Renal disorder 53.21 20.66 60 19043 26626 46640333
Memory impairment 51.52 20.66 104 18999 77233 46589726
Off label use 51.33 20.66 48 19055 379793 46287166
Arrhythmia 51.01 20.66 67 19036 34774 46632185
Lip swelling 50.47 20.66 57 19046 25338 46641621
Drug ineffective 49.42 20.66 130 18973 677708 45989251
Throat clearing 47.91 20.66 14 19089 402 46666557
Cardiac failure acute 46.26 20.66 33 19070 8045 46658914
Pyrexia 46.03 20.66 45 19058 348757 46318202
Mitral valve incompetence 45.69 20.66 47 19056 18805 46648154
Pruritus 45.55 20.66 208 18895 242144 46424815
Cardiac dysfunction 43.54 20.66 18 19085 1473 46665486
Hypoacusis 43.27 20.66 48 19055 20921 46646038
Subclavian vein thrombosis 43.04 20.66 19 19084 1827 46665132
Renal failure 41.39 20.66 121 18982 113473 46553486
Device stimulation issue 40.94 20.66 9 19094 77 46666882
Drug hypersensitivity 40.32 20.66 25 19078 243800 46423159
Weight fluctuation 40.26 20.66 28 19075 6556 46660403
Feeling abnormal 39.77 20.66 127 18976 124933 46542026
Product use in unapproved indication 39.68 20.66 103 19000 90170 46576789
Neutropenia 39.00 20.66 6 19097 143198 46523761
Brain natriuretic peptide increased 38.75 20.66 24 19079 4626 46662333
Cardiac failure congestive 34.64 20.66 99 19004 91651 46575308
Orthopnoea 33.62 20.66 24 19079 5856 46661103
Peripheral swelling 32.94 20.66 140 18963 157931 46509028
Injection site pain 32.84 20.66 3 19100 107149 46559810
Ventricular hypokinesia 31.35 20.66 20 19083 4058 46662901
Acute kidney injury 30.16 20.66 182 18921 235673 46431286
Pain 29.21 20.66 99 19004 476849 46190110
Ventricular tachycardia 28.58 20.66 35 19068 16932 46650027
Weight decreased 28.43 20.66 165 18938 210684 46456275
Overdose 28.39 20.66 4 19099 101975 46564984
Ventricular internal diameter abnormal 28.11 20.66 6 19097 44 46666915
Nausea 28.10 20.66 166 18937 687288 45979671
Cerebrovascular accident 28.01 20.66 98 19005 100941 46566018
Contraindicated product administered 28.00 20.66 84 19019 79863 46587096
Left atrial enlargement 27.20 20.66 8 19095 235 46666724
Gout 26.95 20.66 28 19075 11328 46655631
Disease progression 26.82 20.66 3 19100 91297 46575662
Prohormone brain natriuretic peptide increased 26.45 20.66 7 19096 138 46666821
Chest pain 26.43 20.66 142 18961 176182 46490777
Blood potassium abnormal 26.11 20.66 14 19089 2058 46664901
Swelling face 25.87 20.66 63 19040 52996 46613963
Angina pectoris 25.42 20.66 42 19061 26733 46640226
Dizziness postural 25.21 20.66 21 19082 6425 46660534
Asthenia 25.19 20.66 215 18888 310860 46356099
Cardiogenic shock 24.74 20.66 32 19071 16352 46650607
Left ventricular dysfunction 23.83 20.66 25 19078 10230 46656729
Thrombocytopenia 23.80 20.66 11 19092 126570 46540389
Abdominal pain 23.61 20.66 36 19067 229995 46436964
Palpitations 23.53 20.66 89 19014 95170 46571789
Platelet count decreased 23.44 20.66 6 19097 100018 46566941
Blood urea increased 23.04 20.66 39 19064 25313 46641646
Weight loss poor 22.64 20.66 10 19093 963 46665996
Drug interaction 22.61 20.66 30 19073 203064 46463895
N-terminal prohormone brain natriuretic peptide abnormal 22.23 20.66 5 19098 48 46666911
Brain stem stroke 22.00 20.66 7 19096 269 46666690
Vomiting 21.98 20.66 103 19000 452691 46214268
Diabetes mellitus 21.85 20.66 57 19046 50008 46616951
Acute pulmonary oedema 21.56 20.66 21 19082 7870 46659089
Constipation 21.19 20.66 24 19079 174073 46492886
Seizure 21.18 20.66 12 19091 123042 46543917
Syncope 21.17 20.66 92 19011 104711 46562248
Embolism venous 21.04 20.66 13 19090 2494 46664465
Arthralgia 20.74 20.66 78 19025 364525 46302434

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypotension 1949.43 18.27 1822 38696 198743 29713217
Cardiac failure 1018.72 18.27 866 39652 82552 29829408
Wrong technique in product usage process 796.44 18.27 506 40012 30649 29881311
Dizziness 673.77 18.27 1051 39467 193858 29718102
Ejection fraction decreased 494.07 18.27 288 40230 14887 29897073
Dyspnoea 442.63 18.27 1210 39308 332085 29579875
Product prescribing error 407.85 18.27 264 40254 16469 29895491
Death 382.92 18.27 1202 39316 356081 29555879
Blood pressure decreased 370.91 18.27 384 40134 46691 29865269
Cough 336.74 18.27 606 39912 125036 29786924
Prescribed underdose 333.89 18.27 177 40341 7582 29904378
Blood potassium increased 307.36 18.27 219 40299 15994 29895966
No adverse event 271.16 18.27 209 40309 17210 29894750
Weight increased 268.39 18.27 412 40106 74501 29837459
Inappropriate schedule of product administration 258.37 18.27 293 40225 39435 29872525
Cardiac failure chronic 252.95 18.27 134 40384 5729 29906231
Fluid retention 243.32 18.27 229 40289 24769 29887191
Blood creatinine increased 233.36 18.27 432 40086 90943 29821017
Contraindicated product administered 219.79 18.27 184 40334 17047 29894913
Hyperkalaemia 206 18.27 341 40177 65669 29846291
N-terminal prohormone brain natriuretic peptide increased 205.75 18.27 75 40443 1271 29910689
Ventricular tachycardia 195.58 18.27 199 40319 23663 29888297
Pyrexia 177.17 18.27 89 40429 294400 29617560
Angioedema 176.59 18.27 225 40293 34159 29877801
Hypoacusis 174.16 18.27 148 40370 13991 29897969
Glomerular filtration rate decreased 160.96 18.27 129 40389 11233 29900727
Toxicity to various agents 158.74 18.27 25 40493 177158 29734802
Off label use 153.38 18.27 73 40445 249217 29662743
Renal impairment 148.61 18.27 342 40176 83842 29828118
Blood pressure systolic decreased 143.89 18.27 79 40439 3628 29908332
Neutropenia 141.59 18.27 8 40510 128532 29783428
Ventricular arrhythmia 138.43 18.27 81 40437 4207 29907753
Concomitant disease aggravated 137.50 18.27 86 40432 5043 29906917
Febrile neutropenia 126.23 18.27 4 40514 106689 29805271
Fatigue 122.64 18.27 796 39722 319877 29592083
Underdose 104.47 18.27 104 40414 12037 29899923
Throat clearing 101.61 18.27 29 40489 211 29911749
Cardiogenic shock 100.51 18.27 119 40399 16742 29895218
Cardiac disorder 97.10 18.27 185 40333 39708 29872252
Feeling abnormal 95.05 18.27 226 40292 56530 29855430
Weight decreased 93.60 18.27 428 40090 150493 29761467
Syncope 92.91 18.27 289 40229 84614 29827346
Cardiac failure acute 92.68 18.27 86 40432 9123 29902837
Brain natriuretic peptide increased 91.73 18.27 61 40457 3974 29907986
Weight fluctuation 87.95 18.27 58 40460 3726 29908234
Ejection fraction abnormal 87.83 18.27 34 40484 685 29911275
Completed suicide 86.85 18.27 15 40503 99477 29812483
Orthopnoea 85.22 18.27 61 40457 4479 29907481
Malignant neoplasm progression 84.44 18.27 3 40515 72284 29839676
Peripheral swelling 84.30 18.27 226 40292 60848 29851112
Dizziness postural 76.64 18.27 62 40456 5468 29906492
Mitral valve incompetence 73.31 18.27 90 40428 13144 29898816
Pancytopenia 71.69 18.27 14 40504 85038 29826922
Overdose 70.84 18.27 14 40504 84323 29827637
Left ventricular dysfunction 68.48 18.27 71 40447 8620 29903340
Atrial fibrillation 67.21 18.27 307 40211 107817 29804143
White blood cell count decreased 66.32 18.27 16 40502 83931 29828029
Blood pressure abnormal 65.90 18.27 63 40455 6936 29905024
Thrombocytopenia 64.99 18.27 54 40464 136990 29774970
Sudden cardiac death 64.94 18.27 48 40470 3704 29908256
Therapeutic response unexpected 61.79 18.27 68 40450 8835 29903125
Deep vein thrombosis 60.24 18.27 6 40512 60495 29851465
Seizure 60.13 18.27 29 40489 98446 29813514
Pulmonary oedema 59.92 18.27 162 40356 43813 29868147
Renal failure 59.01 18.27 336 40182 128630 29783330
Cardiorenal syndrome 58.77 18.27 26 40492 742 29911218
Myocardial infarction 58.60 18.27 329 40189 125296 29786664
Memory impairment 56.84 18.27 143 40375 37031 29874929
Congestive cardiomyopathy 55.59 18.27 56 40462 6571 29905389
Anaemia 55.25 18.27 125 40393 207867 29704093
Oedema 55.21 18.27 155 40363 42838 29869122
Hepatojugular reflux 55.07 18.27 20 40498 335 29911625
Renal disorder 54.46 18.27 107 40411 23477 29888483
Malaise 53.71 18.27 398 40120 166564 29745396
Cardiac dysfunction 53.44 18.27 28 40490 1169 29910791
Pneumonia 53.37 18.27 252 40266 334054 29577906
Oedema peripheral 53.26 18.27 283 40235 105549 29806411
Disease progression 51.13 18.27 22 40496 79852 29832108
Lip swelling 51.09 18.27 74 40444 12670 29899290
Product use in unapproved indication 50.87 18.27 216 40302 73477 29838483
Device inappropriate shock delivery 49.74 18.27 12 40506 40 29911920
Constipation 48.16 18.27 49 40469 112857 29799103
Leukopenia 47.83 18.27 9 40509 56150 29855810
Jugular vein distension 46.93 18.27 20 40498 520 29911440
Device malfunction 46.28 18.27 56 40462 8055 29903905
Orthostatic hypotension 46.21 18.27 101 40417 23878 29888082
Left ventricular enlargement 45.23 18.27 20 40498 570 29911390
Plasma cell myeloma 44.62 18.27 9 40509 53453 29858507
Intentional overdose 44.36 18.27 3 40515 41478 29870482
Drug interaction 43.76 18.27 132 40386 199436 29712524
Interstitial lung disease 42.84 18.27 14 40504 60183 29851777
Hospitalisation 42.57 18.27 5 40513 44314 29867646
Tricuspid valve incompetence 41.98 18.27 55 40463 8568 29903392
Illness 41.61 18.27 35 40483 3259 29908701
Hypochromasia 41.12 18.27 16 40502 327 29911633
Weight loss poor 40.30 18.27 13 40505 149 29911811
Dyspnoea paroxysmal nocturnal 40.24 18.27 23 40495 1142 29910818
Ischaemic cardiomyopathy 40.11 18.27 46 40472 6251 29905709
Platelet count decreased 39.89 18.27 51 40467 106078 29805882
Left atrial enlargement 39.26 18.27 17 40501 460 29911500
Arrhythmia 39.11 18.27 116 40402 33053 29878907
Drug hypersensitivity 39.11 18.27 22 40496 68497 29843463
Stomatitis 38.99 18.27 3 40515 37276 29874684
Left ventricular dilatation 37.71 18.27 18 40500 614 29911346
Vomiting 37.20 18.27 162 40356 219656 29692304
Mitral valve thickening 35.73 18.27 13 40505 219 29911741
Abdominal pain 35.58 18.27 82 40436 135572 29776388
Headache 35.51 18.27 127 40391 182179 29729781
Right atrial enlargement 34.58 18.27 13 40505 241 29911719
Heart rate decreased 34.45 18.27 83 40435 20911 29891049
Neuropathy peripheral 34.33 18.27 27 40491 70448 29841512
Dyspnoea at rest 33.56 18.27 28 40490 2578 29909382
Low density lipoprotein abnormal 33.53 18.27 13 40505 263 29911697
Exercise tolerance decreased 33.42 18.27 33 40485 3779 29908181
Near death experience 33.17 18.27 9 40509 53 29911907
Sudden death 33.02 18.27 68 40450 15424 29896536
Blood creatine increased 32.67 18.27 35 40483 4410 29907550
Pruritus 32.56 18.27 272 40246 117932 29794028
Heart rate irregular 32.49 18.27 59 40459 12200 29899760
Chills 32.44 18.27 30 40488 72308 29839652
Cardiac failure congestive 32.25 18.27 210 40308 84197 29827763
Asthenia 32.25 18.27 448 40070 220842 29691118
Drug ineffective 32.25 18.27 300 40218 340087 29571873
Ventricular hyperkinesia 32.04 18.27 12 40506 220 29911740
Mean platelet volume increased 31.99 18.27 14 40504 389 29911571
Pain 31.19 18.27 124 40394 172517 29739443
Pulmonary embolism 30.98 18.27 36 40482 78099 29833861
Alanine aminotransferase increased 30.79 18.27 33 40485 74243 29837717
Intentional product misuse 30.73 18.27 5 40513 34662 29877298
Rheumatoid arthritis 30.35 18.27 9 40509 41188 29870772
Encephalopathy 30.03 18.27 4 40514 32201 29879759
Mental status changes 29.40 18.27 7 40511 37072 29874888
Left ventricular hypertrophy 28.96 18.27 39 40479 6239 29905721
Cardiac aneurysm 28.52 18.27 15 40503 631 29911329
Nasal pruritus 27.93 18.27 8 40510 59 29911901
Acute kidney injury 27.42 18.27 521 39997 273321 29638639
Unevaluable event 27.26 18.27 5 40513 31780 29880180
Heart rate abnormal 27.23 18.27 20 40498 1528 29910432
Intentional product use issue 26.77 18.27 8 40510 36432 29875528
Agitation 25.97 18.27 21 40497 54052 29857908
Decreased activity 25.72 18.27 28 40490 3593 29908367
Aggression 25.53 18.27 9 40509 36898 29875062
Hypervolaemia 25.41 18.27 21 40497 1908 29910052
Hypertensive heart disease 25.12 18.27 23 40495 2397 29909563
Cerebrovascular accident 25.09 18.27 196 40322 83281 29828679
N-terminal prohormone brain natriuretic peptide decreased 24.58 18.27 5 40513 5 29911955
Left ventricular failure 24.55 18.27 32 40486 4959 29907001
Coma 24.53 18.27 12 40506 40437 29871523
Low cardiac output syndrome 24.51 18.27 11 40507 325 29911635
Sepsis 24.05 18.27 109 40409 146286 29765674
Blood urea increased 24.01 18.27 95 40423 31286 29880674
Therapeutic product effect incomplete 23.83 18.27 8 40510 33826 29878134
Blood creatine phosphokinase increased 23.72 18.27 15 40503 43833 29868127
Swollen tongue 23.65 18.27 54 40464 13138 29898822
Aortic valve incompetence 23.34 18.27 31 40487 4892 29907068
Drug reaction with eosinophilia and systemic symptoms 23.34 18.27 5 40513 28483 29883477
Cardio-respiratory arrest 23.15 18.27 26 40492 57280 29854680
Cardiomyopathy 22.87 18.27 58 40460 15085 29896875
Impaired reasoning 22.83 18.27 7 40511 67 29911893
Septic shock 22.43 18.27 32 40486 63575 29848385
Psoriasis 22.37 18.27 15 40503 42491 29869469
Nausea 22.32 18.27 276 40242 296681 29615279
Abnormal behaviour 22.04 18.27 4 40514 25619 29886341
Pyonephrosis 21.96 18.27 7 40511 77 29911883
Hepatic function abnormal 21.81 18.27 15 40503 41930 29870030
Gout 21.79 18.27 62 40456 17253 29894707
Cellulitis 21.45 18.27 19 40499 46765 29865195
Erythema 20.95 18.27 46 40472 77405 29834555
Oxygen saturation decreased 20.70 18.27 17 40501 43423 29868537
COVID-19 20.57 18.27 62 40456 17816 29894144
Cardiovascular somatic symptom disorder 20.52 18.27 6 40512 48 29911912
Diastolic dysfunction 20.41 18.27 27 40491 4244 29907716
Pneumonia aspiration 20.33 18.27 13 40505 37767 29874193
Hypoxia 20.12 18.27 21 40497 47833 29864127
Suicidal ideation 20.02 18.27 12 40506 36102 29875858
Atrial tachycardia 19.50 18.27 19 40499 2140 29909820
Cardiac output decreased 19.38 18.27 13 40505 859 29911101
Type 2 diabetes mellitus 19.36 18.27 51 40467 13571 29898389
Energy increased 19.16 18.27 15 40503 1261 29910699
Peritonitis 19.13 18.27 3 40515 21372 29890588
Cardiovascular insufficiency 19.11 18.27 16 40502 1480 29910480
Liver function test abnormal 19.05 18.27 9 40509 30941 29881019
Dependence on oxygen therapy 18.86 18.27 7 40511 125 29911835
Respiratory arrest 18.80 18.27 8 40510 29250 29882710
Laziness 18.72 18.27 9 40509 312 29911648
Chest pain 18.67 18.27 242 40276 117385 29794575
Aspartate aminotransferase increased 18.56 18.27 36 40482 63386 29848574
Swelling face 18.54 18.27 67 40451 21137 29890823
Acute pulmonary oedema 18.44 18.27 35 40483 7480 29904480

Pharmacologic Action:

SourceCodeDescription
ATC C09DX04 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Angiotensin II receptor blockers (ARBs), other combinations

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chronic heart failure indication 48447003

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.05 acidic
pKa2 12.4 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
24MG;26MG ENTRESTO NOVARTIS PHARMS CORP N207620 July 7, 2015 RX TABLET ORAL Jan. 7, 2021 PEDIATRIC EXCLUSIVITY
49MG;51MG ENTRESTO NOVARTIS PHARMS CORP N207620 July 7, 2015 RX TABLET ORAL Jan. 7, 2021 PEDIATRIC EXCLUSIVITY
97MG;103MG ENTRESTO NOVARTIS PHARMS CORP N207620 July 7, 2015 RX TABLET ORAL Jan. 7, 2021 PEDIATRIC EXCLUSIVITY
24MG;26MG ENTRESTO NOVARTIS PHARMS CORP N207620 July 7, 2015 RX TABLET ORAL Oct. 1, 2022 NEW PATIENT POPULATION
49MG;51MG ENTRESTO NOVARTIS PHARMS CORP N207620 July 7, 2015 RX TABLET ORAL Oct. 1, 2022 NEW PATIENT POPULATION
97MG;103MG ENTRESTO NOVARTIS PHARMS CORP N207620 July 7, 2015 RX TABLET ORAL Oct. 1, 2022 NEW PATIENT POPULATION
24MG;26MG ENTRESTO NOVARTIS PHARMS CORP N207620 July 7, 2015 RX TABLET ORAL April 1, 2023 PEDIATRIC EXCLUSIVITY
49MG;51MG ENTRESTO NOVARTIS PHARMS CORP N207620 July 7, 2015 RX TABLET ORAL April 1, 2023 PEDIATRIC EXCLUSIVITY
97MG;103MG ENTRESTO NOVARTIS PHARMS CORP N207620 July 7, 2015 RX TABLET ORAL April 1, 2023 PEDIATRIC EXCLUSIVITY
24MG;26MG ENTRESTO NOVARTIS PHARMS CORP N207620 July 7, 2015 RX TABLET ORAL Feb. 16, 2024 LABELING REVISIONS RELATED TO CLINICAL STUDIES
49MG;51MG ENTRESTO NOVARTIS PHARMS CORP N207620 July 7, 2015 RX TABLET ORAL Feb. 16, 2024 LABELING REVISIONS RELATED TO CLINICAL STUDIES
97MG;103MG ENTRESTO NOVARTIS PHARMS CORP N207620 July 7, 2015 RX TABLET ORAL Feb. 16, 2024 LABELING REVISIONS RELATED TO CLINICAL STUDIES

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Neprilysin Enzyme INHIBITOR UNKNOWN DRUG LABEL

External reference:

IDSource
D10225 KEGG_DRUG
4034598 VUID
N0000191735 NUI
4034598 VANDF
C5206920 UMLSCUI
C4277755 UMLSCUI
CHEBI:134714 CHEBI
CHEMBL3137301 ChEMBL_ID
9811834 PUBCHEM_CID
7857 IUPHAR_LIGAND_ID
C000717211 MESH_SUPPLEMENTAL_RECORD_UI
C000609743 MESH_SUPPLEMENTAL_RECORD_UI
9819 INN_ID
DB09292 DRUGBANK_ID
17ERJ0MKGI UNII
10430040 PUBCHEM_CID
1656328 RXNORM
31106 MMSL
d08368 MMSL
016257 NDDF
716072000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ENTRESTO HUMAN PRESCRIPTION DRUG LABEL 2 0078-0659 TABLET, FILM COATED 24 mg ORAL NDA 34 sections
ENTRESTO HUMAN PRESCRIPTION DRUG LABEL 2 0078-0696 TABLET, FILM COATED 97 mg ORAL NDA 34 sections
ENTRESTO HUMAN PRESCRIPTION DRUG LABEL 2 0078-0777 TABLET, FILM COATED 49 mg ORAL NDA 34 sections